Shopping Cart
- Remove All
- Your shopping cart is currently empty
OATD-02 is an orally active, competitive, reversible, noncovalent inhibitor with slow offset kinetics that targets both Arginase1 and Arginase2, exhibiting inhibitory concentrations (IC50) of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1). Notably, OATD-02 mitigates tumor immunosuppression provoked by these arginases and has potential application in melanoma research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | OATD-02 is an orally active, competitive, reversible, noncovalent inhibitor with slow offset kinetics that targets both Arginase1 and Arginase2, exhibiting inhibitory concentrations (IC50) of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1). Notably, OATD-02 mitigates tumor immunosuppression provoked by these arginases and has potential application in melanoma research [1]. |
In vitro | OATD-02 inhibits murine ARG in BMDM cells with an IC50 of 912.9 nM, human ARG2 in CHO-K1 cells with an IC50 of 171.6 nM, and hARG1 in primary human hepatocytes with an IC50 of 13 mM [1]. |
In vivo | OATD-02 (10 mg/kg, oral) demonstrates strong, prolonged in vivo efficacy, with oral bioavailability at 13%, 30%, and 61% in mice, rats, and dogs, respectively [1]. At 5 mg/kg orally, it maintains a fourfold increase in plasma L-arginine levels one week post-dosing [1]. Bi-daily oral administration at 50 mg/kg inhibits B16F10 melanoma allograft growth [1]. |
Molecular Weight | 272.15 |
Formula | C12H25BN2O4 |
Cas No. | 2146132-73-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.